Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401792 | 0.85 | NTRK1 (0.49) | IRAK4FLT3NTRK1JAK2JAK1 | |
| SCHEMBL406886 | 0.73 | NTRK1 (0.41) | IRAK4IRAK1NTRK1JAK2 | |
| SCHEMBL400689 | 0.73 | NTRK1 (0.54) | IRAK4FLT3NTRK1JAK2JAK1 | |
| SCHEMBL21997192 | 0.72 | SMPD3 (0.43) | IRAK4FLT3NTRK1JAK2JAK3 | |
| SCHEMBL400691 | 0.72 | IRAK4 (0.56) | IRAK4 | |
| SCHEMBL406176 | 0.72 | IRAK4 (0.56) | IRAK4 | |
| SCHEMBL15428663 | 0.71 | JAK2 (0.46) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL403236 | 0.71 | HTT (0.53) | IRAK4NTRK1JAK2JAK1TYK2 | |
| SCHEMBL15428727 | 0.70 | EPHB3 (0.47) | IRAK4NTRK1JAK2JAK1TYK2 | |
| SCHEMBL406029 | 0.69 | IRAK4 (0.76) | IRAK4FLT3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | IRAK4 9/4885IRAK1 6/4885FLT3 16/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | IRAK4 9/4885IRAK1 6/4885FLT3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.